Stent: Promus Element
2011 sales: $434 million (actual)
Maker: Boston Scientific ($BSX)
Back story: Promus Element represents Boston Scientific's goal of making and selling its own drug-eluting stents, rather than relying on licensing like it did with the predecessor Promus stent (see #3). Since the stent won FDA approval in November 2011, sales have gone gangbusters. But it showed signs of market power early on. After Promus Element gained a CE mark in October 2009, the device went on to generate $10 million in sales before the year was out. In 2010, Promus Element produced $227 million in sales. Designed specifically for coronary stenting, the everolimus-coated stent is delivered with a dual-layer balloon and bisegment inner lumen catheter that's supposed to boost the ability to deliver the stent across difficult lesions. Another standout feature meant to boost safety and effectiveness: The stent has a fluorinated copolymer coating.
Boston Scientific gets FDA nod for heart stent
Boston Sci touts long-term safety of Promus stent, despite FDA warning